Jeffrey Statland1, Colleen M Donlin-Smith2, Stephen J Tapscott3, Silvere van der Maarel4, Rabi Tawil2. 1. Department of Neurology, University of Kansas Medical Center, Kansas City, KS ; Department of Neurology, University of Rochester Medical Center, Rochester, NY. 2. Department of Neurology, University of Rochester Medical Center, Rochester, NY. 3. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands.
Abstract
BACKGROUND: Recent studies have proposed a unified genetic model for Facioscapulohumeral muscular dystrophy (FSHD), identifying potential therapeutic targets for future clinical trials. Serum biomarkers related to disease activity will be important for proof of concept or early phase clinical studies. OBJECTIVE: To identify potential serum biomarkers in FSHD for possible use in future clinical trials. METHODS: We performed a prospective cross-sectional study of serum biomarkers in 22 FSHD patients (19 FSHD1, 3 FSHD2) compared to 23 age and gender-matched healthy controls using a commercial multiplex, microsphere-based immune-fluorescent assay of 243 markers (Myriad, Human Discovery MAP 250, v2.0). RESULTS: 169 markers had values sufficient for analysis. Correction for multiple testing identified 7 biomarkers below a 5% false discovery rate: creatine kinase MB fraction (CKMB, 6.52 fold change, P<0.0001), tissue-type plasminogen activator (PLAT, 1.64 fold change, P<0.0001), myoglobin (2.23 fold change, P=0.0001), epidermal growth factor (EGF, 2.33 fold change, P=0.0004), chemokine (C-C motif) ligand 2 (1.48 fold change, P=0.0004), CD 40 ligand (1.89 fold change, P=0.001), and vitronectin (VTN, 1.28 fold change, P=0.001). Moderate correlations to measures of FSHD disease were seen for CKMB, PLAT, and EGF. Markers in the plasminogen pathway (PLAT, serpin peptidase inhibitor, and VTN) were correlated with each other in FSHD but not healthy controls. CONCLUSIONS: Commercial multiplex immune-fluorescent screening is a potentially powerful tool for identifying biomarkers for future FSHD therapeutic trials. Biomarkers identified in this study warrant further study in a larger prospective validation study.
BACKGROUND: Recent studies have proposed a unified genetic model for Facioscapulohumeral muscular dystrophy (FSHD), identifying potential therapeutic targets for future clinical trials. Serum biomarkers related to disease activity will be important for proof of concept or early phase clinical studies. OBJECTIVE: To identify potential serum biomarkers in FSHD for possible use in future clinical trials. METHODS: We performed a prospective cross-sectional study of serum biomarkers in 22 FSHDpatients (19 FSHD1, 3 FSHD2) compared to 23 age and gender-matched healthy controls using a commercial multiplex, microsphere-based immune-fluorescent assay of 243 markers (Myriad, Human Discovery MAP 250, v2.0). RESULTS: 169 markers had values sufficient for analysis. Correction for multiple testing identified 7 biomarkers below a 5% false discovery rate: creatine kinase MB fraction (CKMB, 6.52 fold change, P<0.0001), tissue-type plasminogen activator (PLAT, 1.64 fold change, P<0.0001), myoglobin (2.23 fold change, P=0.0001), epidermal growth factor (EGF, 2.33 fold change, P=0.0004), chemokine (C-C motif) ligand 2 (1.48 fold change, P=0.0004), CD 40 ligand (1.89 fold change, P=0.001), and vitronectin (VTN, 1.28 fold change, P=0.001). Moderate correlations to measures of FSHD disease were seen for CKMB, PLAT, and EGF. Markers in the plasminogen pathway (PLAT, serpin peptidase inhibitor, and VTN) were correlated with each other in FSHD but not healthy controls. CONCLUSIONS: Commercial multiplex immune-fluorescent screening is a potentially powerful tool for identifying biomarkers for future FSHD therapeutic trials. Biomarkers identified in this study warrant further study in a larger prospective validation study.
Authors: Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan Journal: Hum Mol Genet Date: 2003-09-30 Impact factor: 6.150
Authors: Fedik Rahimov; Oliver D King; Doris G Leung; Genila M Bibat; Charles P Emerson; Louis M Kunkel; Kathryn R Wagner Journal: Proc Natl Acad Sci U S A Date: 2012-09-17 Impact factor: 11.205
Authors: Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott Journal: Dev Cell Date: 2011-12-29 Impact factor: 12.270
Authors: Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets Journal: J Neuromuscul Dis Date: 2016-03-03
Authors: Chao-Jen Wong; Leo Wang; V Michael Holers; Ashley Frazer-Abel; Silvère M van der Maarel; Rabi Tawil; Jeffrey M Statland; Stephen J Tapscott Journal: Hum Mol Genet Date: 2022-06-04 Impact factor: 5.121
Authors: Leslie B Gordon; Susan E Campbell; Joseph M Massaro; Ralph B D'Agostino; Monica E Kleinman; Mark W Kieran; Marsha A Moses Journal: Pediatr Res Date: 2018-02-28 Impact factor: 3.756
Authors: Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott Journal: Hum Mol Genet Date: 2018-08-01 Impact factor: 6.150
Authors: Anna M L Coenen-Stass; Graham McClorey; Raquel Manzano; Corinne A Betts; Alison Blain; Amer F Saleh; Michael J Gait; Hanns Lochmüller; Matthew J A Wood; Thomas C Roberts Journal: Sci Rep Date: 2015-11-23 Impact factor: 4.379